Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter
US9952232B2 · kind B2 · utility
4Cited by
0References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2015 |
| Grant date | Apr 24, 2018 |
| Priority date | — |
| Expiry date | May 19, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16H50/30
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.